Circassia halts investment in allergies after new trial failure

18 April 2017

UK biotech Circassia Pharmaceuticals (LSE: CIR) has seen its house dust mite allergy field study go the same way as its failed cat allergy trial.

Shares in the respiratory disease specialist were worth 2% less by lunchtime on Tuesday at £100.94 after the company announced top-line results from the investigational house dust mite allergy immunotherapy Phase IIb field study.

The findings were that both the active treatment and placebo greatly reduced subjects’ allergy symptoms and rescue medication use.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK